Abstract
Carbohydrates can be found on the cell surface of nearly every cell ranging from bacteria to fungi right up to mammalian cells. Carbohydrates and their interactions with carbohydrate-binding proteins play crucial roles in multiple biological processes including immunity, homeostasis, cellular communication, cell migration, and the regulation of serum glycoprotein levels. In the last decades, the interest in exploiting the biological activity of glycans as vaccine components has considerably increased. On the one hand, carbohydrates display epitopes to generate protective antibodies against pathogen-derived cell wall structures and on the other hand, glycans have the potential to stimulate the immune system; thus they can act as potent vaccine adjuvants.
An effective vaccine consists of two major components, the vaccine antigen and an adjuvant. The vaccine antigen is an original or modified part of the pathogen that causes the disease. The immune response triggered by vaccination should induce antigen-specific plasma cells secreting protective antibodies as well as the development of memory T and B cells. Carbohydrate structures on pathogens represent an important class of antigens that can activate B cells to produce protective anti-carbohydrate antibodies in adults. A major breakthrough in vaccine development was the design of conjugate vaccines that evoke protective antibody responses against encapsulated bacteria strains such as Haemophilus influenzae, Streptococcus pneumoniae, or Neisseria meningitidis in adults, but also in young children. The first part of this chapter focuses on immune responses triggered by carbohydrate-based vaccines. The second part of the chapter discusses the immunological mechanisms of carbohydrate-based adjuvants to increase the immunogenicity of vaccines.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Whitfield C, Trent MS (2014) Biosynthesis and export of bacterial lipopolysaccharides. Annu Rev Biochem 83:99–128
Roberts IS (1996) The biochemistry and genetics of capsular polysaccharide production in bacteria. Annu Rev Microbiol 50:285–315
Marino K, Bones J, Kattla JJ et al (2010) A systematic approach to protein glycosylation analysis: a path through the maze. Nat Chem Biol 6:713–723
Kadioglu A, Weiser JN, Paton JC et al (2008) The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 6:288–301
Avci FY, Kasper DL (2010) How bacterial carbohydrates influence the adaptive immune system. Annu Rev Immunol 28:107–130
Cobb BA, Kasper DL (2005) Coming of age: carbohydrates and immunity. Eur J Immunol 35:352–356
Francis T, Tillett WS (1930) Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. J Exp Med 52:573–585
Schumann B, Anish C, Pereira CL et al (2014) Chemical biology approaches to designing defined carbohydrate vaccines. Chem Biol 21:38–50
Medzhitov R, Janeway CA Jr (1997) Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 9:4–9
Palm NW, Medzhitov R (2009) Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227:221–233
Cruvinel WD, Mesquita D, Araujo JAP et al (2010) Immune system—Part I Fundamentals of innate immunity with emphasis on molecular and cellular mechanisms of inflammatory response. Rev Bras Reumatol 50:434–461
Kapsenberg ML (2003) Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 3:984–993
Romagnani S (2000) T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 85:9–21
Zhu J, Yamane H, Paul WE (2010) Differentiation of Effector CD4 T Cell Populations. Annu Rev Immunol 28:445–489
O’Connor W, Zenewicz LA, Flavell RA (2010) The dual nature of TH17 cells: shifting the focus to function. Nat Immunol 11:471–476
Singh RP, Hasan S, Sharma S et al (2014) Th17 cells in inflammation and autoimmunity. Autoimmun Rev 13:1174–1181
Crotty S (2011) Follicular Helper CD4 T Cells (TFH). Annu Rev Immunol 29:621–663
Parker DC (1993) T cell-dependent B cell activation. Annu Rev Immunol 11:331–360
Murphy K, Travers P, Walport M, Janeway CA (2012) Janeway’s immunobiology. Garland Science, New York
Guttormsen H-K, Sharpe AH, Chandraker AK et al (1999) Cognate stimulatory B-cell–T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun 67:6375–6384
Mond JJ, Lees A, Snapper CM (1995) T cell-independent antigens type 2. Annu Rev Immunol 13:655–692
Landers C, Chelvarajan RL, Bondada S (2005) The role of B cells and accessory cells in the neonatal response to TI-2 antigens. Immunol Res 31:25–36
Weintraub A (2003) Immunology of bacterial polysaccharide antigens. Carbohydr Res 338:2539–2547
Vos Q, Lees A, Wu ZQ et al (2000) B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 176:154–170
López-Herrera G, Vargas-Hernández A, González-Serrano ME et al (2014) Bruton’s tyrosine kinase—an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol 95:243–250
Bondada S, Chelvarajan RL (2004) Neonatal immunity to polysaccharide antigens: role of B cells versus macrophages. Nat Rev Immunol. doi:10.1038/nri1394-c1
Velez CD, Lewis CJ, Kasper DL et al (2009) Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation. Immunology 127:73–82
Avci FY, Li X, Tsuji M et al (2013) Carbohydrates and T cells: a sweet twosome. Semin Immunol 25:146–151
Vinuesa CG, Chang P-P (2013) Innate B cell helpers reveal novel types of antibody responses. Nat Immunol 14:119–126
Alugupalli KR, Akira S, Lien E et al (2007) MyD88- and Bruton’s tyrosine kinase-mediated signals are essential for T cell-independent pathogen-specific IgM responses. J Immunol 178:3740–3749
Dagan R, Poolman J, Siegrist C-A (2010) Glycoconjugate vaccines and immune interference: a review. Vaccine 28:5513–5523
Adamo R, Nilo A, Castagner B et al (2013) Synthetically defined glycoprotein vaccines: current status and future directions. Chem Sci 4:2995–3008
Pobre K, Tashani M, Ridda I et al (2014) Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines. Vaccine 32:1423–1430
Lucas AH, Apicella MA, Taylor CE (2005) Carbohydrate moieties as vaccine candidates. Clin Infect Dis 41:705–712
Avci FY, Li X, Tsuji M et al (2011) A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 17:1602–1609
Kuberan B, Lindhardt RJ (2000) Carbohydrate based vaccines. Curr Org Chem 4:653–677
Astronomo RD, Burton DR (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9:308–324
Makela PH (2003) Conjugate vaccines-a breakthrough in vaccine development. Southeast Asian J Trop Med Public Health 34:249–253
Irving TJ, Blyuss KB, Colijn C et al (2012) Modelling meningococcal meningitis in the African meningitis belt. Epidemiol Infect 140:897–905
Cohn A, Harrison L (2013) Meningococcal vaccines: current issues and future strategies. Drugs 73:1147–1155
Hedari CP, Khinkarly RW, Dbaibo GS (2014) Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resist 7:85–99
Daugla DM, Gami JP, Gamougam K et al (2014) Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 383:40–47
Arguedas A, Soley C, Abdelnour A (2011) Prevenar experience. Vaccine 29:C26–C34
Prymula R, Schuerman L (2009) 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™. Expert Rev Vaccines 8:1479–1500
Gruber WC, Scott DA, Emini EA (2012) Development and clinical evaluation of Prevnar 13, a 13-valent pneumococcal CRM197 conjugate vaccine. Ann NY Acad Sci 1263:15–26
Alving CR, Peachman KK, Rao M et al (2012) Adjuvants for human vaccines. Curr Opin Immunol 24:310–315
Marrack P, McKee AS, Munks MW (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9:287–293
Rappuoli R, Mandl CW, Black S et al (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11:865–872
De Gregorio E, Tritto E, Rappuoli R (2008) Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 38:2068–2071
Eisenbarth SC, Colegio OR, O’Connor W et al (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453:1122–1126
Dostert C, Ludigs K, Guarda G (2013) Innate and adaptive effects of inflammasomes on T cell responses. Curr Opin Immunol 25:359–365
Mohan T, Verma P, Rao D (2013) Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res 138:779–795
Mbow ML, De Gregorio E, Valiante NM et al (2010) New adjuvants for human vaccines. Curr Opin Immunol 22:411–416
Awate S, Babiuk LA, Mutwiri G (2013) Mechanisms of action of adjuvants. Front Immunol. doi: 4 10.3389/fimmu.2013.00114
Duthie MS, Windish HP, Fox CB et al (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239:178–196
Lang R, Schoenen H, Desel C (2011) Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: Findings, implications and open questions. Immunobiology 216:1184–1191
Janeway CA, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216
Cummings RD, McEver RP (2009) C-type lectins. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME (eds) Essentials of glycobiology, 2nd edn. Cold Spring Harbor, New York, NY
Sancho D, Reis e Sousa C (2012) Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol 30:491–529
Geijtenbeek TBH, Gringhuis SI (2009) Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 9:465–479
van Kooyk Y, Geijtenbeek TBH (2003) DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 3:697–709
Drummond RA, Brown GD (2013) Signalling C-type lectins in antimicrobial immunity. PLoS Pathog 9, e1003417
Lepenies B, Lee J, Sonkaria S (2013) Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev 65:1271–1281
Drickamer K (1992) Engineering galactose-binding activity into a C-type mannose-binding protein. Nature 360:183–186
van Kooyk Y, Unger WWJ, Fehres CM et al (2013) Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol Immunol 55:143–145
Miyake Y, Toyonaga K, Mori D et al (2013) C-type lectin MCL is an FcRγ-coupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity 38:1050–1062
Carvalho A, Giovannini G, De Luca A et al (2012) Dectin-1 isoforms contribute to distinct Th1/Th17 cell activation in mucosal candidiasis. Cell Mol Immunol 9:276–286
Petrovsky N, Cooper PD (2011) Carbohydrate-based immune adjuvants. Expert Rev Vaccines 10:523–537
Egli A, Santer D, Barakat K et al (2014) Vaccine adjuvants—understanding molecular mechanisms to improve vaccines. Swiss Med Wkly 144:w13940
Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499–511
Zughaier SM (2011) Neisseria meningitidis capsular polysaccharides induce inflammatory responses via TLR2 and TLR4-MD-2. J Leukoc Biol 89:469–480
Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801
Park BS, Lee J-O (2013) Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med 45, e66
Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82:488–496
Gordon DL, Sajkov D, Woodman RJ et al (2012) Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. Vaccine 30: 5407–5416
Cooper PD, Petrovsky N (2011) Delta inulin: a novel, immunologically active, stable packing structure comprising β-d-[2 → 1] poly(fructo-furanosyl) α-d-glucose polymers. Glycobiology 21:595–606
Lamkanfi M, Malireddi RKS, Kanneganti T-D (2009) Fungal zymosan and mannan activate the cryopyrin inflammasome. J Biol Chem 284:20574–20581
Fernández-Tejada A, Chea EK, George C et al (2014) Development of a minimal saponin vaccine adjuvant based on QS-21. Nat Chem 6:635–643
Marciani DJ (2003) Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8:934–943
Ragupathi G, Gardner JR, Livingston PO et al (2011) Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines 10:463–470
Agnandji ST, Fendel R, Mestré M et al (2011) Induction of plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS, S/AS01(E) and RTS, S/AS02(D). PLoS One 6, e18559
Acknowledgements
This work was supported by the International Max Planck Research School (IMPRS) on Multiscale Bio-Systems. The authors would like to thank Benjamin Schumann for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Zimmermann, S., Lepenies, B. (2015). Glycans as Vaccine Antigens and Adjuvants: Immunological Considerations. In: Lepenies, B. (eds) Carbohydrate-Based Vaccines. Methods in Molecular Biology, vol 1331. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2874-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2874-3_2
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2873-6
Online ISBN: 978-1-4939-2874-3
eBook Packages: Springer Protocols